Trump will sign FDA user fee reau­tho­riza­tion bill, end­ing threat of agency lay­offs

Ahead of its sum­mer re­cess, the US Sen­ate to­day fol­lowed its House coun­ter­parts and passed a bi­par­ti­san bill to reau­tho­rize FDA user fee pro­grams for pre­scrip­tion drugs, gener­ic drugs, med­ical de­vices and biosim­i­lars for the next five years. A spokesman for Pres­i­dent Don­ald Trump told Fo­cus, “The Pres­i­dent will sign this bill, but we look for­ward to work­ing with Con­gress to ad­dress fur­ther ne­go­ti­a­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER